Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease.
Graft-versus-host disease (GvHD) complicates many allogeneic stem cell transplants (alloSCT), and several factors are known to be associated with the development of GvHD besides human leucocyte antigen (HLA) incompatibility. We investigated whether changes in serum levels of soluble IL-2 receptor (sIL-2Ralpha), tumour necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF) and soluble Fas (sFas) correlated with the development of GvHD in patients undergoing SCT, and might thus be potentially of use to anticipate the development of GvHD, allowing early modification of immunosuppressive therapy.sIL2Ralpha and sFas levels were significantly raised in allograft, autograft (allo and auto) and non-graft groups compared to the normal controls (HC), but there was no statistical difference between the three patient groups. TNF-alpha was raised in the auto and allo groups and the non-graft patients compared to the HC group (median 4.37 pg/ml), but only reached significance in the allo group (median 6.02 pg/ml; p = 0.008) when this was compared with the non-graft patients. There was no significant difference in TGF-ss levels between any of the groups. The median serum VEGF levels were decreased in allo and auto patients compared to HC, (31 and 62 pg/ml versus 90 pg/ml, respectively), with a significant difference in the auto group (p = 0.007). VEGF levels were significantly lower in the auto versus the allo group (p = 0.008) and also in the auto versus the non-graft group (median 104 pg/ml; p = 0.011). When the allo group was divided into patients who developed GvHD and those who did not, serum VEGF levels were significantly higher in those with GvHD (p = 0.028).
Lunn
R A
RA
Department of Clinical Immunology, St Helier Hospital, Surrey, SM5 1AA, Carshalton, UK.
Sumar
N
N
Bansal
A S
AS
Treleaven
J
J
D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood*; D005199:Fanconi Anemia / Q000097:blood / Q000628:therapy; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit; D008223:Lymphoma / Q000097:blood / Q000628:therapy; D008297:Male; D011237:Predictive Value of Tests; D018123:Receptors, Interleukin / Q000097:blood; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D019014:fas Receptor / Q000097:blood
D015415:Biomarkers; D016207:Cytokines; C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit; D018123:Receptors, Interleukin; D042461:Vascular Endothelial Growth Factor A; D019014:fas Receptor